MCID: CHL123
MIFTS: 59

Chlamydia

Categories: Infectious diseases, Reproductive diseases

Aliases & Classifications for Chlamydia

MalaCards integrated aliases for Chlamydia:

Name: Chlamydia 12 74 3 15
Chlamydial Infection 12 54 15
Chlamydia Trachomatis Infectious Disease 12 17
Chlamydia Infections 71
Chlamydial Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11263
ICD10 32 A74.9
UMLS 71 C0008149

Summaries for Chlamydia

CDC : 3 Chlamydia is a common sexually transmitted disease (STD) that can be easily cured. If left untreated, chlamydia can make it difficult for a woman to get pregnant.

MalaCards based summary : Chlamydia, also known as chlamydial infection, is related to chlamydia pneumonia and trachoma, and has symptoms including fever, pruritus and pelvic pain. An important gene associated with Chlamydia is YWHAB (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Beta), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lymecycline and Levonorgestrel have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and heart, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A commensal bacterial infectious disease that is caused by Chlamydia trachomatis.

Wikipedia : 74 Chlamydia, or more specifically a chlamydia infection, is a sexually transmitted infection caused by the... more...

Related Diseases for Chlamydia

Diseases related to Chlamydia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1058)
# Related Disease Score Top Affiliating Genes
1 chlamydia pneumonia 34.0 TNF TLR4 TLR2 IL6 IL10 HSPD1
2 trachoma 33.4 TNF MBL2 IL6 IL10 IDO1 HSPD1
3 pelvic inflammatory disease 32.8 TLR4 TLR2 IFNG HSPD1 CRP CD40LG
4 reactive arthritis 32.2 TNF TLR4 TLR2 IL6 IL1B IL10
5 conjunctivitis 32.0 TNF IL6 IL10 IFNG CXCL8
6 cervicitis 31.9 TLR4 TLR2 IL6 HSPD1 CXCL8
7 salpingitis 31.6 TNF TLR2 HSPD1 CRP CD40LG
8 prostatitis 31.5 TNF IL6 IL1B IL10 CXCL8
9 vaginal discharge 31.5 IL6 CXCL8 CRP CD40LG
10 urethritis 31.5 TNF TLR4 TLR2 IL6 HSPD1 CXCL8
11 atherosclerosis susceptibility 31.4 TNF TLR4 IL6 IL1B HSPD1 CXCL8
12 keratoconjunctivitis 31.4 TNF IL6 IFNG CXCL8
13 endometritis 31.3 TNF TLR4 TLR2 IL6 IL1B CXCL8
14 haemophilus influenzae 31.3 TNF TLR2 CXCL8
15 carotid stenosis 31.1 TNF CXCL8 CRP
16 trichomoniasis 31.1 TNF IL6 CXCL8 CD40LG
17 chronic conjunctivitis 31.1 TNF IL6 IL10 CXCL8
18 cytomegalovirus infection 31.1 TNF IL6 IL1B CXCL8
19 coronary artery anomaly 31.0 TNF IL6 IL1B IL10 CXCL8 CRP
20 rhinitis 31.0 TNF IL6 IL10 IFNG CXCL8
21 pyuria 31.0 IL6 CXCL8 CRP CD40LG
22 arteriosclerosis 31.0 TLR4 IL6 IL10 IFNG HSPD1 CRP
23 pharyngitis 30.9 TNF IL6 IL1B CXCL8 CRP CD40LG
24 vulvovaginitis 30.9 IL10 HSPD1 CXCL8
25 lymphoma, mucosa-associated lymphoid type 30.9 TLR4 TLR2 HSPD1 CD40LG
26 cerebrovascular disease 30.8 TNF TLR4 IL6 CRP CD40LG
27 cervical cancer 30.8 TNF TLR4 MCL1 IL6 IL10 IFNG
28 orchitis 30.8 TNF IL6 IL10 CRP CD40LG
29 meningoencephalitis 30.8 TNF IL6 IL10 CRP CD40LG
30 spondylitis 30.8 TNF IL6 IL10 IFNG CRP
31 bacterial vaginosis 30.8 TNF TLR4 TLR2 MBL2 IL6 IL1B
32 iridocyclitis 30.8 TNF IL6 CRP CD40LG
33 erythema multiforme 30.8 TNF IL6 IFNG CXCL8
34 vaginitis 30.8 TNF TLR4 TLR2 IL6 IL1B IL10
35 placenta disease 30.7 TNF IL6 IL1B CXCL8 CRP
36 uveitis 30.7 TNF IL6 IL10 IFNG HSPD1 CXCL8
37 spondylarthropathy 30.7 TNF TLR4 TLR2
38 synovitis 30.7 TNF IL6 IL1B CXCL8 CRP
39 bronchitis 30.7 TNF TLR4 TLR2 IL6 IL1B IL10
40 thyroiditis 30.7 TNF IL6 IL10
41 allergic hypersensitivity disease 30.7 TNF TLR4 TLR2 IL10 IFNG CXCL8
42 respiratory failure 30.7 TNF IL6 IL1B IL10 CXCL8 CRP
43 coronary stenosis 30.7 TLR4 IL6 CRP
44 spondyloarthropathy 30.7 TNF IL6 IL1B IL10 IFNG
45 combined t cell and b cell immunodeficiency 30.7 IL6 IL10 CD40LG
46 arthritis 30.6 TNF TLR4 TLR2 IL6 IL1B IL10
47 cryptogenic organizing pneumonia 30.6 TNF CXCL8 CRP
48 temporal arteritis 30.6 TNF IL6 IFNG CRP CD40LG
49 spondyloarthropathy 1 30.6 TNF TLR4 HSPD1 CRP CD40LG
50 disseminated intravascular coagulation 30.6 TNF IL6 IL10 CRP

Graphical network of the top 20 diseases related to Chlamydia:



Diseases related to Chlamydia

Symptoms & Phenotypes for Chlamydia

UMLS symptoms related to Chlamydia:


fever, pruritus, pelvic pain

GenomeRNAi Phenotypes related to Chlamydia according to GeneCards Suite gene sharing:

26 (show all 36)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.29 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.29 MAPK14
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.29 IL10
4 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.29 YWHAB
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.29 CRP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.29 IL10
7 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.29 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-129 10.29 YWHAB
9 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.29 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.29 MAPK14 YWHAB
11 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.29 MAPK14 YWHAB
12 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.29 CRP
13 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.29 RAF1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.29 RAF1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.29 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.29 CRP IL10 MAPK14 RAF1 YWHAB
17 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.29 IL10
18 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.29 CRP
19 Increased shRNA abundance (Z-score > 2) GR00366-A-182 10.29 MAPK14
20 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.29 YWHAB
21 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.29 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.29 IL10 YWHAB
23 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.29 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.29 IL10
25 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.29 YWHAB
26 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.29 CRP
27 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.29 IL10 RAF1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.29 MAPK14
29 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.29 CRP MAPK14
30 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.29 IL10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.29 IL10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.29 IL10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.29 IL10 MAPK14
34 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.88 CASP1 CD40LG CXCL8 IL10 IL1B MCL1
35 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.88 CASP1 CD40LG CXCL8 IL10 IL1B MCL1
36 Decreased viability after Chlamydia trachomatis serovar L2 infection and TNF-alpha/CHX stimulation GR00206-A 9.55 MAPK14 MCL1 NOS2 RAC1 RAF1

MGI Mouse Phenotypes related to Chlamydia:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.44 CASP1 CD40LG CRP IDO1 IFNG IL10
2 cellular MP:0005384 10.43 CASP1 CD40LG HSPD1 IDO1 IFNG IL10
3 hematopoietic system MP:0005397 10.43 CASP1 CD40LG IDO1 IFNG IL10 IL1B
4 immune system MP:0005387 10.42 CASP1 CD40LG CRP IDO1 IFNG IL10
5 homeostasis/metabolism MP:0005376 10.41 CASP1 CD40LG CRP IDO1 IFNG IL10
6 integument MP:0010771 10.32 CASP1 CD40LG IFNG IL10 IL1B IL6
7 endocrine/exocrine gland MP:0005379 10.31 CASP1 CD40LG IFNG IL10 IL6 MAPK14
8 mortality/aging MP:0010768 10.31 CASP1 CD40LG HSPD1 IFNG IL10 IL1B
9 muscle MP:0005369 10.18 HSPD1 IDO1 IFNG IL10 IL6 MAPK14
10 nervous system MP:0003631 10.17 CASP1 CD40LG HSPD1 IFNG IL10 IL1B
11 digestive/alimentary MP:0005381 10.15 CASP1 IFNG IL10 IL6 NOS2 TLR2
12 liver/biliary system MP:0005370 10.11 IFNG IL10 IL6 MAPK14 NOS2 RAF1
13 neoplasm MP:0002006 10.11 CASP1 IFNG IL10 IL1B IL6 MAPK14
14 reproductive system MP:0005389 9.97 CASP1 CD40LG HSPD1 IDO1 IFNG IL10
15 renal/urinary system MP:0005367 9.91 CASP1 CD40LG IDO1 IFNG IL6 MBL2
16 respiratory system MP:0005388 9.61 IFNG IL10 IL6 MAPK14 NOS2 RAF1
17 skeleton MP:0005390 9.4 CD40LG IFNG IL10 IL1B IL6 MAPK14

Drugs & Therapeutics for Chlamydia

Drugs for Chlamydia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 224)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
2
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
3
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
4
Polyestradiol phosphate Approved Phase 4 28014-46-2
5
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
6
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
7
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
8
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
9
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
10
Norgestrel Approved Phase 4 6533-00-2 13109
11
Drospirenone Approved Phase 4 67392-87-4 68873
12
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
13
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
14
Norelgestromin Approved, Investigational Phase 4 53016-31-2 13752005
15
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
16
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
17
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
18
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
19
Oxytetracycline Approved, Investigational, Vet_approved Phase 4 79-57-2 5280972 54715139
20
Metronidazole Approved Phase 4 443-48-1 4173
21
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
22
leucovorin Approved Phase 4 58-05-9 6006 143
23
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
24
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
25
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
26
Sodium citrate Approved, Investigational Phase 4 68-04-2
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
28
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
29 Contraceptives, Oral Phase 4
30 Contraceptive Agents Phase 4
31 Immunologic Factors Phase 4
32 Contraceptives, Oral, Combined Phase 4
33 Estrogens Phase 4
34 Estradiol 17 beta-cypionate Phase 4
35 Estradiol 3-benzoate Phase 4
36 Antiviral Agents Phase 4
37 Clindamycin palmitate Phase 4
38 Clindamycin phosphate Phase 4
39 Mineralocorticoids Phase 4
40 Norgestimate, ethinyl estradiol drug combination Phase 4
41 Mineralocorticoid Receptor Antagonists Phase 4
42 Natriuretic Agents Phase 4
43 Diuretics, Potassium Sparing Phase 4
44 Drospirenone and ethinyl estradiol combination Phase 4
45 diuretics Phase 4
46 Anticonvulsants Phase 4
47 Amoxicillin-Potassium Clavulanate Combination Phase 4
48 beta-Lactamase Inhibitors Phase 4
49 Ortho Evra Phase 4
50 Heptavalent Pneumococcal Conjugate Vaccine Phase 4

Interventional clinical trials:

(show top 50) (show all 323)
# Name Status NCT ID Phase Drugs
1 Study of Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Antibiotic Treatment Unknown status NCT01661985 Phase 4 Azithromycin;Doxycycline;lymecycline
2 A Community-level RCT of Expedited Partner Treatment for Gonorrhea and Chlamydia Completed NCT01665690 Phase 4
3 Tripartite International Research for the Elimination of Trachoma Completed NCT01202331 Phase 4 mass treatment with oral azithromycin
4 Eliminating Trachoma With Repeat Mass Drug Treatment Completed NCT00322972 Phase 4 Mass treatment with oral azithromycin to an entire community
5 Trachoma Elimination With Repeated Mass Azithromycin Treatments Completed NCT00221364 Phase 4 Mass treatment with oral azithromycin to an entire village
6 Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Completed NCT00618449 Phase 4 Azithromcyin;Azithromycin
7 Efficacy and Side-Effects of Two Dosing Regimens of Doxycycline at Surgical Abortion: A Randomized Double-Blind Trial Completed NCT00547170 Phase 4 Doxycycline pre-operatively;Doxycycline post-operatively
8 Detection and Treatment Benefit of Microorganism (Chlamydia Trachomatis, Mycoplasma Hominis, Ureaplasma Urealyticum) in Overactive Bladder Patients Completed NCT00883818 Phase 4 azithromycin, doxycycline
9 Extended Antimicrobial Treatment of Bacterial Vaginosis Combined With Human Lactobacilli to Find the Best Treatment and Minimize the Risk of Relapses Completed NCT01245322 Phase 4 lactobacilli
10 Strategies for the Control of Blinding Trachoma: Effect of Fly Spray Completed NCT00347763 Phase 4
11 Integrating Prenatal Care to Reduce HIV/STDs Among Teens: A Translational Study Completed NCT00628771 Phase 4
12 An Open Label Study to Evaluate Cycle Control With Ortho Tri-Cyclen Lo (Norgestimate/Ethinyl Estradiol) and Yaz (Drospirenone/Ethinyl Estradiol) in Healthy Sexually Active Females Completed NCT00745901 Phase 4 Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol
13 Women With Epilepsy: a Pilot Study of Pharmacokinetic and Pharmacodynamic Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users Completed NCT02362373 Phase 4 levonorgestrel IUS
14 An Open-Label, Randomized, Multicenter Trial to Evaluate Continuation Rates, Side Effects and Acceptability of NuvaRing Versus OrthoEvra Completed NCT00269620 Phase 4 ethinyl estradiol/etonogestrel vaginal ring;ethinyl estradiol/norelgestromin transdermal contraceptive
15 Research to Programs for Trachoma Elimination: Antibiotic Trial Completed NCT00792922 Phase 4 Azithromycin;Azithromycin
16 Cost-effectiveness of Three Alternative Azithromycin Treatment Strategies for Trachoma Control in Tanzania Completed NCT00347607 Phase 4
17 Periodical Presumptive Treatment of Gonorrhoea in Female Sex Workers: Impact on Prevalence of the Disease in Sex Workers and Their Clients Completed NCT01329588 Phase 4 Monthly antibiotic;Monthly placebo
18 Costs and Effects of Early Switch of Intravenous to Oral Antibiotics in Severe Community-Acquired Pneumonia: a Multicenter Randomized Trial Completed NCT00273676 Phase 4
19 Determination of the Impact of Water and Health Education on Trachoma and Ocular C. Trachomatis in Niger Completed NCT00348478 Phase 4
20 A Randomised Controlled Trial of Non-absorbable (Silk) Sutures Verses Absorbable (Vicryl) Sutures During the Surgical Treatment of Trachomatous Trichiasis Completed NCT00522860 Phase 4
21 Double-Blind Placebo-Controlled Clinical Effectiveness Trial of the 23-Valent Pneumococcal Vaccine Among Military Trainees At Increased Risk of Respiratory Disease Completed NCT02079701 Phase 4
22 A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
23 Gender-Affirmative Medical Care to Improve HIV Treatment Cascade Among Transgender Women Completed NCT03757117 Phase 4 Feminizing hormone therapy
24 Pneumonia in Children: Aetiology, Ideal Antibiotic Duration, Quality of Life Completed NCT02258763 Phase 4 Amoxicillin-Potassium Clavulanate Combination;Placebo
25 Randomized, Controlled Clinical Trial of Day-care Based and Hospitalized Management of Severe and Very Severe Pneumonia, With Severe Malnutrition, With/Without Associated Co-morbidities in Children Completed NCT00968370 Phase 4
26 A Phase 4, Randomized, Double-Blinded, Placebo-Controlled Trial of Azithromycin Versus Doxycycline for the Treatment of Rectal Chlamydia in Men Who Have Sex With Men Recruiting NCT03608774 Phase 4 Azithromycin;Doxycycline
27 Impact of Antichlamydial Treatment on the Rate of Preeclampsia Among Egyptian Primigravidae: a Randomized Controlled Trial Recruiting NCT03233880 Phase 4 Azithromycin 1gm
28 Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) Recruiting NCT02042287 Phase 4 Metronidazole
29 The Effect of Antibiotics on Latency in Previable Prelabor Rupture of Membranes Between 18 0/7 and 22 6/7 Weeks Gestational Age Recruiting NCT04047849 Phase 4 Antibiotics, oral Azithromycin and oral Amoxicillin
30 Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance: Morbidity Study Enrolling by invitation NCT02048007 Phase 4 Azithromycin;Placebo
31 Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial Enrolling by invitation NCT02149030 Phase 4
32 Randomized, Open-label, Multicenter Study of Azithromycin Compared With Doxycycline for Treating Anorectal Chlamydia Trachomatis Infection Concomitant to a Vaginal Infection Not yet recruiting NCT03532464 Phase 4 azithromycin;doxycycline
33 Kebele Elimination of Trachoma for Ocular Health Not yet recruiting NCT03335072 Phase 4 Azithromycin
34 Enhancing Nutrition and Antenatal Infection Treatment for Maternal and Child Health in Amhara Region, Ethiopia Not yet recruiting NCT04171388 Phase 4 Azithromycin 500 mg;Placebo oral tablet 500 mg
35 PrEP and dPEP: Doxycycline Post-exposure Prophylaxis for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV Pre-exposure Prophylaxis Not yet recruiting NCT04050540 Phase 4 Doxycycline
36 Trachoma Elimination Study by Focused Antibiotic (TESFA): The Impact of an Enhanced Antibiotic Treatment Regimen on Trachoma in Amhara, Ethiopia Not yet recruiting NCT03523156 Phase 4 Azithromycin mass treatment;Azithromycin targeted treatment
37 Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men Not yet recruiting NCT03980223 Phase 4 Doxycycline Hyclate Delayed-Release 200 mg
38 Randomized Open-label Study of the Impact of Prolonged Systemic Corticosteroid Therapy on the Course and Relapse Risk of Checkpoint Inhibitor Interstitial Lung Disease (Pneumonitis) Related to the Treatment of Solid Tumors With Anti-programmed-death Type 1 Receptor or Ligand Antibodies Not yet recruiting NCT04036721 Phase 4 Prolonged glucocorticosteroid (prednisone) regimen;Short glucocorticosteroid (prednisone) regimen
39 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study Terminated NCT01879930 Phase 4 doxycycline;placebo
40 Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Terminated NCT00194597 Phase 4 Viagra (sildenafil citrate)
41 Azithromycin in Control of Trachoma II Withdrawn NCT00286026 Phase 4 Azithromycin
42 Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
43 Prospective Evaluation of Rifalazil Effect On Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients Unknown status NCT00251849 Phase 3 Rifalazil
44 Identigene STD Test Collection Kit Validation Study Unknown status NCT01471392 Phase 3
45 Maternal Genitourinary Infections and Adverse Perinatal Outcomes in Sylhet District, Bangladesh Unknown status NCT01572532 Phase 3
46 Randomized Clinical Trial Evaluating Treatment Failure Following Recommended Therapy (Azithromycin Versus Doxycycline) for Genital Chlamydial Infection in Males and Females in Youth Correctional Facilities Completed NCT00980148 Phase 3 Azithromycin;Doxycycline
47 Clinical Trial of Eye Prophylaxis in the Newborn Completed NCT00000120 Phase 3 Erythromycin Ointment;Silver Nitrate Drops
48 Partner Notification for Chlamydia in Primary Care: Randomised Controlled Trial and Economic Evaluation Completed NCT00112255 Phase 3
49 Safety and Efficacy of WC2031 Versus Vibramycin for the Treatment of Uncomplicated Urogenital Chlamydia Trachomatis Infection: A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter Study Completed NCT01113931 Phase 3 Doxycyline Hyclate tablet;Vibramycin (doxycyline hyclate) capsule
50 Home Screening for Chlamydia Surveillance Completed NCT00177437 Phase 3

Search NIH Clinical Center for Chlamydia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


acetyl sulfisoxazole
ERYTHROMYCIN PWDR
Sulfisoxazole

Genetic Tests for Chlamydia

Anatomical Context for Chlamydia

MalaCards organs/tissues related to Chlamydia:

40
Testes, T Cells, Heart, Prostate, Lung, Eye, Endothelial

Publications for Chlamydia

Articles related to Chlamydia:

(show top 50) (show all 25002)
# Title Authors PMID Year
1
Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. 54 61
20524235 2010
2
[Chlamydia pneumoniae in the etiology of the keratoconjunctivitis sicca in adult patients (a pilot study)]. 54 61
19642357 2009
3
Chlamydia trachomatis detection in a population of asymptomatic and symptomatic women: correlation with the presence of serological markers for this infection. 54 61
18623991 2008
4
Caspase-1 contributes to Chlamydia trachomatis-induced upper urogenital tract inflammatory pathologies without affecting the course of infection. 54 61
18025098 2008
5
Chlamydia trachomatis infection, Fallopian tube damage and a mannose-binding lectin codon 54 gene polymorphism. 54 61
17496053 2007
6
[Concentrational changes of mannose-binding proteins in blood plasma during noncomplicated pregnancy and in blood plasma of pregnant women with some infections]. 54 61
16575126 2006
7
Chlamydia pneumoniae infection promotes a proliferative phenotype in the vasculature through Egr-1 activation in vitro and in vivo. 54 61
15722416 2005
8
Human antibody responses to a Chlamydia-secreted protease factor. 54 61
15557641 2004
9
Chlamydia pneumoniae as a respiratory pathogen. 54 61
11861211 2002
10
Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. 54 61
11801686 2002
11
Heat shock protein 60 specific T-cell response in chlamydial infections. 54 61
11439151 2001
12
Host immune response to Chlamydia pneumoniae heat shock protein 60 is associated with asthma. 54 61
11491147 2001
13
Presence of Chlamydia pneumoniae in human symptomatic and asymptomatic carotid atherosclerotic plaque. 54 61
11283382 2001
14
Chlamydia trachomatis infection of epithelial cells induces the activation of caspase-1 and release of mature IL-18. 54 61
10903751 2000
15
Immunity to heat shock proteins and pregnancy outcome. 54 61
10231007 1999
16
Human mannose-binding protein inhibits infection of HeLa cells by Chlamydia trachomatis. 54 61
9529088 1998
17
Humoral immune response to membrane components of Chlamydia trachomatis and expression of human 60 kDa heat shock protein in follicular fluid of in-vitro fertilization patients. 54 61
9194641 1997
18
Potentiation of interferon-mediated inhibition of Chlamydia infection by interleukin-1 in human macrophage cultures. 54 61
7537250 1995
19
Chlamydia trachomatis antigens: role in immunity and pathogenesis. 54 61
7866655 1994
20
Continuous B-cell epitopes in Chlamydia trachomatis heat shock protein 60. 54 61
7679373 1993
21
IgA antichlamydia antibodies as a diagnostic tool for monitoring of active chlamydial infection. 54 61
1294398 1992
22
Amniotic fluid findings in women with high levels of chlamydial antibody. 54 61
2227607 1990
23
Inflammatory bowel disease versus Chlamydia trachomatis infection: a case report and revision of the literature. 61
31851086 2020
24
Understanding Relationships Between Chlamydial Infection, Symptoms, and Testing Behavior: An Analysis of Data from Natsal-3. 61
31794495 2020
25
Chlamydia trachomatis and Neisseria gonorrhoeae Retesting and Reinfection Rates in New Zealand Health Care Settings: Implications for Sexually Transmitted Infection Control. 61
31880741 2020
26
Performance of 4 Molecular Assays for Detection of Chlamydia and Gonorrhea in a Sample of Human Immunodeficiency Virus-Positive Men Who Have Sex With Men. 61
32032316 2020
27
County-Level Social Capital and Bacterial Sexually Transmitted Infections in the United States. 61
31842088 2020
28
Evaluation of 2 Commercial Assays for the Detection of Lymphogranuloma Venereum in Rectal Samples. 61
31876865 2020
29
Chlamydia psittaci infection as a cause of respiratory disease in neonatal foals. 61
31436332 2020
30
High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas. 61
32012328 2020
31
Association between quality-of-care indicators for HIV infection and healthcare resource utilization and costs. 61
31714351 2020
32
Diverging trends in incidence of HIV versus other sexually transmitted infections in HIV-negative MSM in Amsterdam. 61
31714354 2020
33
Substance Use and Sexual Risk Behavior Among Male and Transgender Women Sex Workers at the Prostitution Outreach Center in Amsterdam, the Netherlands. 61
31935207 2020
34
Testing for Sexually Transmitted Diseases in US Public Health Laboratories, 2016. 61
31935208 2020
35
Declining trends in HIV and other sexually transmitted infections among female sex workers in Iran could be attributable to reduced drug injection: a cross-sectional study. 61
31836679 2020
36
Chlamydia Infection Among Adolescent Long-Acting Reversible Contraceptive and Shorter-Acting Hormonal Contraceptive Users Receiving Services at New York City School-Based Health Centers. 61
31542369 2020
37
Supplemental Trichomonas vaginalis testing is required to maintain control following a transition from Pap smear to HPV DNA testing for cervical screening: a mathematical modelling study. 61
30992326 2020
38
Facing increased sexually transmitted infection incidence in HIV preexposure prophylaxis cohorts: what are the underlying determinants and what can be done? 61
31789694 2020
39
The well-evolved pathogen. 61
32018150 2020
40
Screening and Counseling Adolescents and Young Adults: A Framework for Comprehensive Care. 61
32003959 2020
41
Reported Prevalence of Maternal Hepatitis C Virus Infection in the United States. 61
31923064 2020
42
Cell-mediated immune response associated with Chlamydia pneumoniae infection in atherosclerotic patients. 61
31707079 2020
43
Analysis of humoral immune responses to recombinant Chlamydia pneumoniae antigens. 61
31841725 2020
44
Chlamydia-induced curvature of the host-cell plasma membrane is required for infection. 61
31964834 2020
45
Pooling of urine samples for molecular detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium as a screening strategy among young adults in Catalonia. 61
31288994 2020
46
STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany. 61
32033533 2020
47
Bacterial vaginosis-associated vaginal microbiota is an age-independent risk factor for Chlamydia trachomatis, Mycoplasma genitalium and Trichomonas vaginalis infections in low-risk women, St. Petersburg, Russia. 61
32036466 2020
48
A profile of the cobas® CT/NG assay on the cobas® 6800/8800 system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. 61
32008410 2020
49
A meta-analysis of affinity purification-mass spectrometry experimental systems used to identify eukaryotic and chlamydial proteins at the Chlamydia trachomatis inclusion membrane. 61
31760040 2020
50
Guidance on Expedited Partner Therapy: A Content Analysis of Informational Materials for Providers, Pharmacists, Patients, and Partners. 61
31935209 2020

Variations for Chlamydia

Expression for Chlamydia

Search GEO for disease gene expression data for Chlamydia.

Pathways for Chlamydia

Pathways related to Chlamydia according to GeneCards Suite gene sharing:

(show top 50) (show all 123)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 YWHAB TNF TLR4 TLR2 RAF1 RAC1
2
Show member pathways
13.95 TNF RAF1 RAC1 NOS2 MAPK14 IL6
3
Show member pathways
13.85 TNF TLR4 RAF1 RAC1 NOS2 MAPK14
4
Show member pathways
13.67 TNF RAF1 RAC1 MAPK14 IL6 IL1B
5
Show member pathways
13.58 YWHAB TNF TLR4 TLR2 RAF1 RAC1
6
Show member pathways
13.53 YWHAB TNF RAF1 NOS2 MCL1 IL6
7
Show member pathways
13.43 TNF RAC1 IL6 IL1B IL10 CXCL8
8
Show member pathways
13.35 TNF TLR4 TLR2 RAF1 RAC1 MAPK14
9
Show member pathways
13.16 YWHAB TNF TLR4 TLR2 RAF1 RAC1
10
Show member pathways
13.14 TNF TLR4 TLR2 RAF1 RAC1 MAPK14
11
Show member pathways
13.09 YWHAB TNF RAF1 RAC1 MAPK14 IL6
12
Show member pathways
13.06 TNF RAC1 IL6 IL1B IL10 IFNG
13 12.98 RAF1 RAC1 NOS2 IL6 IFNG CXCL8
14
Show member pathways
12.97 TNF TLR4 MAPK14 IL6 IL1B IFNG
15
Show member pathways
12.96 TNF TLR4 TLR2 RAF1 RAC1 MAPK14
16 12.91 TNF RAF1 RAC1 MAPK14 IL1B CASP1
17
Show member pathways
12.85 TNF TLR4 TLR2 IL6 IL1B CD40LG
18
Show member pathways
12.81 TNF RAF1 MAPK14 IL1B IFNG CD40LG
19
Show member pathways
12.81 TNF TLR4 TLR2 MCL1 MAPK14 IL6
20
Show member pathways
12.8 TNF RAC1 NOS2 MAPK14 IL6 IL1B
21
Show member pathways
12.78 TNF RAF1 RAC1 IL10 IFNG CD40LG
22
Show member pathways
12.78 TNF TLR4 TLR2 RAF1 MAPK14 IL6
23 12.77 TNF TLR2 IL1B IL10 IFNG IDO1
24
Show member pathways
12.73 YWHAB TNF TLR4 TLR2 RAF1 RAC1
25
Show member pathways
12.62 RAF1 RAC1 NOS2 MAPK14 IL1B
26 12.61 TNF TLR4 RAC1 MAPK14 IL1B CXCL8
27
Show member pathways
12.56 TNF TLR2 MAPK14 IL6 IL1B IFNG
28
Show member pathways
12.55 TLR4 TLR2 RAF1 RAC1 MAPK14
29 12.52 TNF TLR4 RAC1 MAPK14 IL6 IL1B
30
Show member pathways
12.5 RAF1 RAC1 NOS2 MAPK14 CXCL8
31
Show member pathways
12.5 RAF1 MCL1 IL6 IL10 IFNG
32 12.5 TNF TLR4 TLR2 RAF1 RAC1 MAPK14
33
Show member pathways
12.49 YWHAB TLR4 TLR2 RAF1 MAPK14
34
Show member pathways
12.48 TNF IL6 IL1B IFNG CRP
35 12.46 TNF TLR4 MAPK14 IL6 IL1B CXCL8
36
Show member pathways
12.45 TNF TLR4 RAF1 RAC1 NOS2 MAPK14
37
Show member pathways
12.44 TNF RAF1 MAPK14 IL6 IL1B IL10
38
Show member pathways
12.44 TNF TLR2 RAF1 NOS2 MAPK14 IL6
39
Show member pathways
12.43 TNF IL6 IL10 CXCL8
40
Show member pathways
12.43 YWHAB RAF1 RAC1 MAPK14
41
Show member pathways
12.43 YWHAB TNF TLR4 TLR2 RAF1 RAC1
42
Show member pathways
12.42 TNF TLR4 TLR2 IL6 CXCL8
43
Show member pathways
12.42 TNF IL6 IL1B IL10 IFNG CXCL8
44 12.41 YWHAB TNF MCL1 CD40LG CASP1
45
Show member pathways
12.41 TNF TLR4 TLR2 NOS2 MAPK14 IL1B
46
Show member pathways
12.4 RAC1 MAPK14 IL6 IFNG
47 12.4 TNF TLR4 TLR2 NOS2 IL6 IFNG
48 12.4 YWHAB TNF IL6 IL1B IL10 HSPD1
49
Show member pathways
12.4 TNF TLR4 TLR2 NOS2 IL6 IL1B
50
Show member pathways
12.37 TNF TLR4 IL1B IFNG CASP1

GO Terms for Chlamydia

Cellular components related to Chlamydia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.73 TNF TLR4 TLR2 MBL2 HSPD1 CD40LG
2 extracellular region GO:0005576 9.65 TNF MBL2 MAPK14 IL6 IL1B IL10
3 extracellular space GO:0005615 9.32 TNF MBL2 IL6 IL1B IL10 IFNG
4 lipopolysaccharide receptor complex GO:0046696 9.16 TLR4 HSPD1

Biological processes related to Chlamydia according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.37 TLR4 TLR2 RAF1 MAPK14 IL6 IL1B
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.3 TNF TLR4 TLR2 RAF1 MAPK14 IL6
3 apoptotic process GO:0006915 10.21 TLR2 RAF1 MCL1 MAPK14 IL1B IFNG
4 negative regulation of apoptotic process GO:0043066 10.2 RAF1 MCL1 IL6 IL10 HSPD1 CD40LG
5 negative regulation of cell proliferation GO:0008285 10.16 TLR2 RAF1 IL6 IL1B IL10 CXCL8
6 defense response to bacterium GO:0042742 10.1 TNF TLR4 NOS2 MBL2 IL10
7 MAPK cascade GO:0000165 10.1 YWHAB TNF RAF1 MAPK14 IL1B
8 immune response GO:0006955 10.09 TNF TLR4 TLR2 IL6 IL1B IL10
9 positive regulation of gene expression GO:0010628 10.06 TNF TLR4 TLR2 MAPK14 IL6 IL1B
10 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.04 TNF TLR4 IL1B CASP1
11 positive regulation of protein phosphorylation GO:0001934 10.04 TNF RAF1 RAC1 IL1B IFNG
12 activation of MAPK activity GO:0000187 10.01 TNF TLR4 MAPK14 IL1B
13 positive regulation of DNA-binding transcription factor activity GO:0051091 10.01 TNF IL6 IL1B IL10
14 cellular response to interferon-gamma GO:0071346 9.98 TLR4 TLR2 NOS2 CASP1
15 positive regulation of inflammatory response GO:0050729 9.97 TNF TLR4 TLR2 IL1B
16 cellular response to mechanical stimulus GO:0071260 9.97 TLR4 RAC1 IL1B CASP1
17 defense response to Gram-positive bacterium GO:0050830 9.96 TNF TLR2 MBL2 IL6 CRP
18 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.95 TNF TLR4 TLR2 IL6 IL1B CD40LG
19 regulation of insulin secretion GO:0050796 9.94 TNF NOS2 IL1B IFNG
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.93 TNF IL6 IFNG
21 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.93 TNF TLR4 TLR2 IL1B
22 response to glucocorticoid GO:0051384 9.92 TNF IL6 IL10
23 apoptotic signaling pathway GO:0097190 9.92 TNF TLR4 CASP1
24 positive regulation of T cell proliferation GO:0042102 9.92 IL6 IL1B CD40LG
25 humoral immune response GO:0006959 9.92 TNF IL6 IFNG
26 cytokine-mediated signaling pathway GO:0019221 9.92 TNF NOS2 MCL1 IL6 IL1B IL10
27 response to lipopolysaccharide GO:0032496 9.91 TLR4 TLR2 NOS2 MAPK14 IL1B IL10
28 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.9 TNF MCL1 IL1B
29 acute-phase response GO:0006953 9.9 MBL2 IL6 CRP
30 negative regulation of interleukin-6 production GO:0032715 9.9 TNF TLR4 IL10
31 B cell proliferation GO:0042100 9.9 IL10 HSPD1 CD40LG
32 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.89 TLR4 TLR2 HSPD1
33 positive regulation of JAK-STAT cascade GO:0046427 9.89 TNF IL6 IL10
34 positive regulation of phagocytosis GO:0050766 9.89 TNF MBL2 IL1B IFNG
35 microglial cell activation GO:0001774 9.88 TNF TLR2 IFNG
36 negative regulation of neurogenesis GO:0050768 9.88 TNF IL6 IL1B
37 positive regulation of nitric oxide biosynthetic process GO:0045429 9.88 TNF TLR4 IL1B IFNG
38 positive regulation of interferon-gamma production GO:0032729 9.87 TNF TLR4 IL1B HSPD1
39 positive regulation of interleukin-6 secretion GO:2000778 9.85 TNF TLR4 TLR2 IL1B
40 positive regulation of glial cell proliferation GO:0060252 9.84 TNF IL6 IL1B
41 positive regulation of interleukin-8 production GO:0032757 9.84 TNF TLR4 TLR2 IL1B
42 astrocyte activation GO:0048143 9.83 TNF IL1B IFNG
43 positive regulation of macrophage activation GO:0043032 9.83 TLR4 IL10 HSPD1
44 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.83 TNF IL1B IFNG
45 positive regulation of interleukin-10 production GO:0032733 9.83 TLR4 TLR2 HSPD1 CD40LG
46 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.82 TNF IL1B IL10
47 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.81 TLR4 TLR2 IFNG
48 positive regulation of neuroinflammatory response GO:0150078 9.8 TNF IL6 IL1B
49 positive regulation of chemokine production GO:0032722 9.8 TNF TLR4 TLR2 IL6
50 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 TNF TLR4 TLR2 MAPK14 IL1B

Molecular functions related to Chlamydia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 YWHAB TNF TLR4 TLR2 RAF1 RAC1
2 identical protein binding GO:0042802 9.91 YWHAB TNF TLR4 TLR2 RAF1 CRP
3 enzyme binding GO:0019899 9.72 YWHAB RAF1 RAC1 MAPK14 HSPD1
4 lipopolysaccharide binding GO:0001530 9.33 TLR4 TLR2 HSPD1
5 lipopolysaccharide receptor activity GO:0001875 9.26 TLR4 TLR2
6 cytokine activity GO:0005125 9.17 TNF IL6 IL1B IL10 IFNG CXCL8

Sources for Chlamydia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....